

FIN-Seq: Transcriptional profiling of specific cell types in frozen archived tissue from the human central nervous system

Ryoji Amamoto^{1,3,*} Emanuela Zuccaro^{1,4,*} Nathan C. Curry¹ Sonia Khurana¹ Hsu-Hsin Chen¹ Constance L. Cepko^{3,†}
Paola Arlotta^{1,2,†}

¹Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.

²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

³Department of Genetics and Ophthalmology, Howard Hughes Medical Institute, Blavatnik Institute, Harvard Medical School, Boston MA 02115, USA.

⁴Current address: Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy.

*These authors contributed equally

†Co-Corresponding Authors: Paola Arlotta (paola.arlotta@harvard.edu), Constance L. Cepko (cepko@genetics.med.harvard.edu)

0 ABSTRACT

1 **Thousands of frozen, archived tissues from postmortem human**
2 **central nervous system (CNS) are currently available**
3 **in brain banks. As single cell and single nucleus technologies**
4 **are beginning to elucidate the cellular diversity present**
5 **within the human CNS, it is becoming clear that transcriptional**
6 **analysis of the human CNS requires cell type specificity.**
7 **Single cell and single nucleus RNA profiling provide**
8 **one avenue to decipher this heterogeneity. An alternative,**
9 **complementary approach is to profile isolated, pre-defined**
10 **cell types and use methods that can be applied to many**
11 **archived human tissue samples. Here, we developed FIN-**
12 **Seq (Frozen Immunolabeled Nuclei Sequencing), a method**
13 **that accomplishes these goals. FIN-Seq uses immunohisto-**
14 **chemical isolation of nuclei of specific cell types from frozen**
15 **human tissue, followed by RNA-Sequencing. We applied this**
16 **method to frozen postmortem samples of human cerebral**
17 **cortex and retina and were able to identify transcripts, in-**
18 **cluding low abundance transcripts, in specific cell types.**

19 INTRODUCTION

20 The human central nervous system (CNS) comprises an extremely
21 diverse set of cell types. While this heterogeneous cellular
22 composition has been appreciated since the work of early
23 anatomists, it was not until recently, with the advent of single
24 cell and single nucleus RNA sequencing, that different cell types
25 of the adult human cerebral cortex and retina have begun to be
26 defined at the molecular level (Cherry et al., 2018; Darmanis
27 et al., 2015; Hodge et al., 2018; Lake et al., 2016; Lake et al.,
28 2018; Liang et al., 2019; Lukowski et al., 2018; Peng et al.,
29 2019; Phillips et al., 2018). These studies have identified at
30 least 16 neuronal subtypes in the adult human cerebral cortex
31 and 18 major cell types in the adult human retina. While these
32 pioneering studies have started to highlight the heterogeneity
33 of the adult human CNS, more fine-grained distinctions among
34 cell types are likely present, and will become more apparent
35 with increased numbers of cells profiled. Given such heterogeneity,
36 gaining mechanistic insight into human CNS development,
37 function, and disease will require transcriptional profiling

at both single cell and cell type-specific resolution. 38

Transcriptional profiling of heterogeneous populations is 39
feasible with either single cell RNA sequencing (Macosko et al., 40
2015; Shekhar et al., 2016; Tasic et al., 2016; Zeisel et al., 2015) 41
or bulk RNA sequencing of purified user-defined cell types la- 42
beled either genetically or with dyes and antibodies (Arlotta et 43
al., 2005; Heiman et al., 2008; Lobo et al., 2006; Molyneaux et 44
al., 2015; Siekert et al., 2012; Telley et al., 2016). Single cell 45
RNA sequencing has become essential for cataloguing molec- 46
ularly distinct cell types in heterogeneous tissues such as the 47
CNS. However, sampling the whole tissue for rare cell types, 48
such as cone photoreceptors, is expensive as large numbers of 49
single cells need to be profiled. Alternatively, bulk RNA se- 50
quencing of user-defined cell types allows for the acquisition of 51
transcriptomes of rarer cell types; thus, avoiding sequencing of a 52
large number of more abundant cell types. Acquisition of more 53
transcriptomes via single cell RNA sequencing is accelerating 54
the discovery of potential new markers that could be used to iso- 55
late specific, rare cell populations from cellularly diverse tissues. 56
We aimed to develop a method that enables bulk RNA sequenc- 57
ing of specific cell types and extends to archived frozen tissue. 58
Thousands of frozen human postmortem brain tissue samples, 59
including those with disease, are readily available through brain 60
banks, and they represent a crucial resource that is immediately 61
available and largely untapped. The abundance of archived CNS 62
tissue samples is crucial for profiling transcriptional changes in 63
rare diseases, and it is also likely that the number of biological 64
replicates needed in human studies is high because of the natural 65
genetic variation present among individuals. 66

While whole-cell approaches are incompatible with flash- 67
frozen CNS tissue, the nuclei from frozen tissue stay intact and 68
can be profiled. In addition, nuclear RNA has been successfully 69
used as proxy for the cellular transcriptome (Barthelson et al., 70
2007; Grindberg et al., 2013; Habib et al., 2017; Krishnaswami 71
et al., 2016; Lake et al., 2016; Lake et al., 2017). Single nucleus 72
RNA sequencing has indeed been used for unbiased profile of 73
neuronal subtypes from frozen, archived human cerebral cortex 74
tissue (Lake et al., 2016). However, a complementary technol- 75
ogy to isolate and bulk sequence nuclear RNA of user-defined 76
cell types from frozen human CNS tissue is lacking. 77

Here, we developed FIN-Seq (Frozen Immunolabeled 78

79 Nuclei Sequencing), a technology that combines nuclear iso- 136
80 lation, fixation, immunolabeling, FACS, and RNA sequencing 137
81 to obtain the gene expression profile of specific neuronal sub- 138
82 types from frozen, archived human CNS tissue. While some 139
83 antibodies such as those against NeuN and SOX6 are known 140
84 to work with fresh tissue (Kozlenkov et al., 2018), a method 141
85 to apply a wider range of antibodies against cell type specific 142
86 markers is not available. With FIN-Seq, we isolated and pro- 143
87 filed specific excitatory and inhibitory neuronal subtypes from 144
88 frozen human cerebral cortex tissue and cone photoreceptors 145
89 from the frozen human retina. Successful isolation of cone pho- 146
90 toreceptors, which constituted roughly 2% of the whole retina, 147
91 signified that rare populations could be reliably profiled from a 148
92 frozen tissue sample. Interestingly, we also found that the nu- 149
93 clear transcripts captured with FIN-Seq represented more of the 150
94 whole-cell transcripts compared to single nucleus sequencing. 151
95 This is a novel, cost-effective technology that could enable deep 152
96 transcriptional analysis of user-defined cell types from widely- 153
97 available frozen human CNS samples. 154

98 RESULTS 155

99 FACS isolation of immunolabeled nuclei from frozen mouse 156 100 brain samples 157

101 To test whether sequencing of specific nuclear RNA from frozen 158
102 tissue is feasible, we first tested it using specific nuclear popula- 159
103 tions isolated from the frozen mouse neocortex. To this end, 160
104 we modified previously-published protocols that use intracel- 161
105 lular antibody staining to isolate specific cell types (Hrvatín 162
106 et al., 2014; Molyneaux et al., 2015; Pan et al., 2011; Pech- 163
107 hold et al., 2009; Yamada et al., 2010). Intact cells cannot 164
108 be dissociated from frozen tissue, so we developed a proto- 165
109 col to isolate fixed antibody-labeled nuclei and extract nuclear 166
110 RNA (**Figure 1a**). Nuclei isolation eliminates the need for 167
111 enzymatic dissociation, which induces aberrant activation of 168
112 immediate early genes (Lacár et al., 2016). From the flash- 169
113 frozen neocortex of P30 mice, we sought to isolate two popula- 170
114 tions of projection neurons, Corticofugal Projection Neurons 171
115 (CFuPN) and Callosal Projection Neurons (CPN). In the adult 172
116 mouse brain, BCL11B (also known as CTIP2) is largely ex- 173
117 pressed in CFuPNs in layer 5b and 6 and in sparse popula- 174
118 tions of interneurons. SATB2 is expressed by CPNs in all layers 175
119 (Molyneaux et al., 2007) (**Figure 1b**). BCL11B and SATB2 ex- 176
120 pression are largely mutually exclusive, with a small population 177
121 of layer 5 neurons expressing both markers (Harb et al., 2016; 178
122 Molyneaux et al., 2015) (**Figure 1b, Layer 5, inset**). Upon 179
123 isolation by homogenization, nuclei were fixed, immunolabeled 180
124 with antibodies against BCL11B and SATB2, and separated into 181
125 two populations by FACS: SATB2^{LO}BCL11B^{HI} (BCL11B⁺) and 182
126 SATB2^{HI}BCL11B^{LO} (SATB2⁺) (n=2 for each population) (**Fig- 183
127 ure 1c-d**). On average, we collected 55,215 BCL11B⁺ nuclei 184
128 and 102,016 SATB2⁺ nuclei per biological replicate. These re- 185
129 sults indicate that this protocol could isolate intact nuclei that 186
130 are immunolabeled with user-defined intranuclear antibodies. 187

131 To determine whether we isolated the correct neuronal pop- 188
132 ulations and to test nuclear transcriptional profiling using these 189
133 samples, SMART-Seq v.4 RNA-seq libraries were generated and 190
134 sequenced on HiSeq 2500. For each sample, libraries were se- 191
135 quenced to a mean of 40 million 100bp paired-end reads (range: 192
193

36-48 million reads per sample) to be able to reliably detect low- 136
abundance transcripts. To determine the degree of RNA degrada- 137
tion, we measured the 3' bias using Qualimap (Okonechnikov 138
et al., 2016). The 3' bias for P30 samples ranged from 0.65 to 139
0.69 (mean±SD: 0.685±0.02), which is comparable to RNA In- 140
tegrity Number (RIN) of 2-4 (Sigurgeirsson et al., 2014) (**Fig- 141
ure 1e**). Consistent with the idea that nuclear transcripts are 142
predominantly nascent RNA, we found that a substantial num- 143
ber of reads mapped to intronic regions (Exonic: 63.16±4.89%; 144
Intronic: 32.49±4.48%; Intergenic: 4.36±0.56%), (**Figure 1f**) 145
(Habib et al., 2017; Lake et al., 2016; Lake et al., 2017). Distri- 146
bution of normalized read counts was virtually identical among 147
samples (**Figure 1-figure supplement 1a**). Unbiased hierar- 148
chical clustering showed that the samples of the same popu- 149
lation clustered together (average Pearson correlation between 150
samples within population: r = 0.98) (**Figure 1-figure supple- 151
ment 1b**). Subsequently, the two populations were analyzed 152
for differential (gene) expression (DE). The frequency distri- 153
bution of all *p*-values showed an even distribution of null *p*- 154
values, thus allowing for calculation of adjusted *p*-value using 155
the Benjamini-Hochberg procedure (**Figure 1-figure supple- 156
ment 1c**). Between populations, we found 2,698 differentially 157
expressed genes (adjusted *p*-value < 0.05) out of 17,662 genes. 158
The high number of genes detected suggests identification of 159
low abundance transcripts. 160

From the DE analysis, we found an enrichment of known 161
CPN and Layer 4 (L4) markers (e.g. *Cux2*, *Unc5d*, and *Rorb*) in 162
the SATB2⁺ population among the unbiased top 50 DE genes. 163
Conversely, we found an enrichment of CFuPN markers (e.g. 164
Fezf2, *Foxp2*, and *Crym*) in the BCL11B⁺ population (**Figure 165
1g**). BCL11B also labels interneurons in all layers of the mouse 166
neocortex (Arlotta et al., 2005; Nikouei et al., 2016). Accord- 167
ingly, we found an enrichment of some interneuron markers in 168
the BCL11B⁺ population (e.g. *Gad1* and *Gad2*) (**Figure 1g**). To 169
confirm the molecular identities of the isolated neuronal popu- 170
lations, we also determined the relative expression levels of 171
known CPN and CFuPN marker genes that were differentially 172
expressed between CPN and CFuPN in previous studies (21 173
CPN markers and 22 CFuPN markers) (Arlotta et al., 2005; 174
Molyneaux et al., 2007; Molyneaux et al., 2015). We found 175
that all CPN markers were enriched in the SATB2⁺ population 176
and all CFuPN markers were enriched in the BCL11B⁺ popula- 177
tion (**Figure 1-figure supplement 2**). To validate the differen- 178
tially expressed genes, we chose four DE genes (*Ddit4l*, *Unc5d*, 179
Kcnn2, and *Rprm*) for further analysis. Using RNAscope dou- 180
ble fluorescent *in situ* hybridization (FISH), we localized the 181
transcripts of these genes in specific neuronal populations. We 182
found that *Ddit4l* and *Unc5d* were expressed in layers 2 through 183
4 and were localized to SATB2⁺ neurons (**Figure 1-figure sup- 184
plement 3**). Additionally, *Kcnn2* and *Rprm* were expressed in 185
layers 5 and 6, respectively, and they were specifically confined 186
to BCL11B⁺ neurons (**Figure 1-figure supplement 3**). In addi- 187
tion, we successfully isolated and profiled the same neuronal 188
populations from mature, adult (1+ years old) mouse neocor- 189
tex (**Figure 1-figure supplement 4-5**). These results indicate 190
that FIN-Seq can be used to isolate CFuPN and CPN nuclei 191
from flash-frozen mouse neocortex for downstream quantitative 192
RNA-seq analysis of specific neuronal populations. 193




Figure 1: Isolation and transcriptome sequencing of two neuronal subtypes from the frozen mouse neocortex. (A) Schematic of FIN-Seq for frozen adult mouse brain. Nuclei were extracted from the frozen mouse neocortex by Dounce homogenization. The nuclei were fixed and immunolabeled with anti-BCL11B and anti-SATB2 antibodies. Two nuclear populations were isolated by FACS based on expression level of these two proteins. The nuclei were reverse crosslinked by protease digestion, and the RNA was extracted. Sequencing libraries were generated and subsequently sequenced to obtain cell type specific transcriptomes. (B) Representative immunohistochemistry images using BCL11B and SATB2 antibodies in the P30 mouse neocortex showed SATB2 expression in the upper layers and BCL11B expression in the deep layers (Left image). In layer 5, there were sparse cells that express both SATB2 and BCL11B (Bottom right image). (C) FACS plot of nuclei labeled with SATB2 and BCL11B antibodies showed a cluster of nuclei immunolabeled with BCL11B and a cluster of nuclei labeled with SATB2. (D) Isolated nuclei were counterstained by the Hoechst dye and either SATB2 or BCL11B in the SATB2⁺ population (top panels) or BCL11B⁺ population (bottom panels). (E) Representative quantification of read counts mapped by transcript position (5' to 3') for every gene. (F) Representative quantification of percentage of read counts mapped to exonic, intronic, or intergenic regions of the genome. (G) Heatmap of unbiased top 50 differentially expressed genes between SATB2⁺ and BCL11B⁺ populations. Known markers of callosal projection neurons (in red) were enriched in the SATB2⁺ population while known markers of corticofugal projection neurons (in green) were enriched in the BCL11B⁺ population. Scale bars; 100 μ m (b, right panels, d), 500 μ m (b, left panel).

194 To determine the degree to which nuclear transcript abundance
 195 correlates to cellular transcript abundance, we sought to
 196 compare the transcriptional profiles of BCL11B⁺ nuclei and
 197 cells. For cells, we dissociated the brains of P7 mice using a
 198 protocol described previously (Molyneaux et al., 2015). For nuclei,
 199 we performed the FIN-Seq protocol, starting with a fresh
 200 P7 brain instead of flash-freezing to keep the starting material

consistent between cells and nuclei. We chose the P7 time point
 because dissociation of the adult mouse brain into single cells
 affects cell viability at later ages. Transcriptional analysis of
 BCL11B⁺ cells and nuclei showed a high degree of correlation
 (average Pearson correlation between cellular vs. nuclear: $r = 0.90$;
 cellular vs. cellular: $r = 0.93$; nuclear vs. nuclear: $r = 0.93$)
 (Figure 1-figure supplement 6). In contrast, previous compar-

208 ison of single nucleus and single cell transcriptomes from the
209 adult mouse brain showed a lower degree of correlation ($r =$
210 0.77) (Lake et al., 2017). These results indicate that bulk se-
211 quencing of isolated nuclei using FIN-Seq could more accu-
212 rately represent the transcript abundance found within whole
213 cells.

214 **Specific neuronal subtypes can be isolated from frozen post-** 215 **mortem human brain samples**

216 To determine whether this protocol is applicable to frozen post-
217 mortem samples of the human brain, we obtained five frozen
218 postmortem brain samples (Brodmann Area 4, primary motor
219 cortex; Ages: 47-61) from a tissue bank that had stored them
220 long-term (for description of the samples, see Materials and
221 Methods). Of note, the oldest frozen sample had been archived
222 for over 25 years. We implemented the same FIN-Seq proto-
223 col as above to the frozen human cortical tissue (**Figure 2a**),
224 in which we found BCL11B⁺/SATB2⁻, BCL11B⁺/SATB2⁺, and
225 BCL11B⁻/SATB2⁺ nuclei (**Figure 2b**). We used FACS to isolate
226 SATB2^{LO}BCL11B^{HI} and SATB2^{HI}BCL11B^{LO} nuclei as well
227 as all cortical nuclei (henceforth called BCL11B⁺, SATB2⁺,
228 and All, respectively) for comparison (BCL11B⁺: 26,616 nu-
229 clei/replicate, n=5; SATB2⁺: 104,865 nuclei/replicate, n=5; All:
230 67,580 nuclei/replicate, n=5). These results indicate that nuclear
231 isolation of specific neuronal subtypes from frozen postmortem
232 human brain tissue is feasible using this technique.

233 To identify the molecular identity of the isolated neuronal
234 populations, we performed RNA sequencing of each population
235 (BCL11B⁺, SATB2⁺, and All, sequenced to a mean of 36 mil-
236 lion paired-end 100bp reads). The average RIN of the frozen
237 human brain samples prior to FIN-Seq was 3.9. After FIN-Seq,
238 the 3' bias ranged from 0.69 to 0.78 (mean±SD: 0.73±0.02),
239 which corresponds to a RIN of 2-4, indicating that the FIN-Seq
240 protocol does not further decrease the integrity of the RNA (**Fig-**
241 **ure 2-figure supplement 1a**). The human brain contains an in-
242 creased number of nascent transcripts compared to other organs
243 and organisms (Ameur et al., 2011). Accordingly, we found that
244 the proportion of intronic reads was higher in the human neu-
245 ronal samples compared to that in mice (Exonic: 47.76±5.82%;
246 Intronic: 45.51±5.04%; Intergenic: 6.72±1.13%) (**Figure 2-**
247 **figure supplement 1b**). Quality control of the sequencing reads
248 and differential expression analysis indicated successful sam-
249 ple separation and differential expression analysis (**Figure 2-**
250 **figure supplement 2**). Between SATB2⁺ and All populations,
251 we found 4,917 differentially expressed genes (adjusted p -value
252 < 0.05) out of 24,979 genes. Between BCL11B⁺ and All popu-
253 lations, we found 2,812 differentially expressed genes (adjusted
254 p -value < 0.05) out of 24,477 genes.

255 To determine the molecular identity of the SATB2⁺ and
256 BCL11B⁺ populations, we first compared the gene expression
257 levels of known markers of oligodendrocytes, astrocytes, and
258 neurons. We found that neuronal markers were enriched in both
259 SATB2⁺ and BCL11B⁺ populations. We also found an enrich-
260 ment in the BCL11B⁺ population of *PDGFRA*, normally con-
261 sidered an oligodendrocyte marker, but also previously shown
262 to be expressed by a subset of inhibitory neurons in the hu-
263 man cerebral cortex (**Figure 2-figure supplement 3**) (Lake et
264 al., 2016). The SATB2⁺ population highly expressed *SLC17A7*
265 (also known as *VGLUT1*) and did not express *GAD1* or *GAD2*,

266 while the BCL11B⁺ population expressed *GAD1* and *GAD2* at
267 high levels, indicating that, while SATB2⁺ population contained
268 mainly excitatory neurons, BCL11B⁺ population contained also
269 inhibitory neurons (**Figure 2-figure supplement 4**).

270 We next sought to understand the identity of the SATB2⁺ and
271 BCL11B⁺ populations at the neuronal subtype-level. Previously,
272 single nucleus RNA-seq has identified eight excitatory neuronal
273 subtypes (Ex1-Ex8) and eight inhibitory neuronal subtypes (In1-
274 In8) in the adult human neocortex (Lake et al., 2016). SATB2
275 is expressed in all excitatory neurons, but it is most highly ex-
276 pressed in one of the neuronal subtypes referred to, in this prior
277 study, as Ex4. BCL11B is highly expressed in In1, In4, In5, and
278 In6. SATB2 and BCL11B are both expressed in Ex6 and Ex8,
279 but we would not expect to see these subtypes in our popula-
280 tions as we did not collect the SATB2^{HI}BCL11B^{HI} population.
281 For the SATB2⁺ population, we cross-referenced our DE gene
282 set (adjusted p -value < 0.05) to the molecular signature genes
283 that define the eight excitatory cortical neuronal subtypes (Ex1-
284 Ex8). From this analysis, we observed a high level of expres-
285 sion of Ex4 markers in the SATB2⁺ population compared to the
286 All population (**Figure 2c**). To confirm these results, we also
287 ran the dataset through a gene set enrichment analysis (GSEA)
288 against all marker genes that define Ex1-Ex8 (Subramanian et
289 al., 2005). We found that Ex4 gene set was significantly en-
290 riched in the SATB2⁺ population while Ex6 and Ex8 gene sets
291 were enriched in the All population (default significance at FDR
292 < 0.25; Ex4: FDR = 0.139; Ex6: FDR = 0.043; Ex8: FDR =
293 0.005). Depletion of Ex6 and Ex8 from the SATB2⁺ popula-
294 tion is likely due to the exclusion of SATB2^{HI}BCL11B^{HI} nuclei.
295 We confirmed the expression of *COL6A1* and *ANXA1*, two Ex4
296 markers, in SATB2⁺ neurons by single molecule FISH (**Figure**
297 **2d**). In the BCL11B⁺ population, we found that the markers
298 for In1, In4, In5, and In6 were enriched compared to the All
299 population (**Figure 2e**). Furthermore, previous single cell se-
300 quencing of the fresh adult human brain identified seven neu-
301 ronal communities (NC), of which SATB2 is highly expressed in
302 neuronal community 4 (NC4) (Darmanis et al., 2015). Accord-
303 ingly, we found that the markers for NC4 are highly expressed
304 in the isolated SATB2⁺ population (**Figure 2-figure supple-**
305 **ment 5**). By GSEA analysis, we also found that NC4 gene
306 set was significantly enriched in the SATB2⁺ population (FDR
307 = 0.037). Taken together, our results show the FIN-Seq proto-
308 col can isolate molecularly-defined neuronal subtypes for down-
309 stream transcriptional profiling from frozen postmortem human
310 cortical samples.

311 **Isolation and transcriptional profiling of cone photorecep-** 312 **tors from the human retina**

313 To determine whether we could use FIN-Seq to isolate and pro-
314 file specific cell types from another region of the human CNS,
315 we chose to isolate cone photoreceptors from the retina. We
316 obtained four frozen postmortem eyes (age range: 40-60, see
317 Materials and methods for description of samples) from patients
318 without known retinal disorders. Nuclei were extracted from
319 the mid-peripheral retina, fixed, and immunostained by a hu-
320 man Cone Arrestin (CAR, also known as ARR3) antibody (**Fig-**
321 **ure 3a**). In human retinal cross-sections, we found CAR expres-
322 sion in the nuclei and cell bodies of cone photoreceptors, located
323 in the outer nuclear layer where all photoreceptors reside (**Fig-**




Figure 2: Isolation and profiling of neuronal subtypes from the frozen human cerebral cortex. (A) Schematic of FIN-Seq for frozen human cerebral cortex. Nuclei were isolated and subsequently fixed in 4% PFA. They were immunolabeled with anti-BCL11B and anti-SATB2 antibodies, and FACS isolated into populations. RNA from the nuclei were sequenced to obtain a cell type specific transcriptome. (B) Representative immunohistochemistry of the adult human cerebral cortex using anti-BCL11B and anti-SATB2 antibodies. Some nuclei expressed both SATB2 and BCL11B (arrows), some nuclei expressed BCL11B but not SATB2 (arrowheads), and many nuclei expressed SATB2 but not BCL11B. (C) A heatmap representing relative expression levels of excitatory neuron markers previously identified by single nuclei RNA sequencing that are differentially expressed (adjusted p -value < 0.05) between SATB2⁺ and All populations. Markers of neuronal subtype Ex4 (outlined in red), which expresses SATB2, were enriched in the SATB2⁺ population. (D) Validation of Ex4 markers, *COL6A1* (left panel) and *ANXA1* (right panel) using RNAscope single molecule FISH. Both *COL6A1* and *ANXA1* were expressed in SATB2⁺ neurons (arrows). (E) A heatmap representing relative expression levels of inhibitory neuron markers previously identified by single nuclei RNA sequencing that are differentially expressed (adjusted p -value < 0.05) between BCL11B⁺ and All populations. Markers of neuronal subtypes, In1, In4, In5, and In6, all of which express BCL11B, were enriched in the BCL11B⁺ population. Scale bars: 100 μ m (b), 50 μ m (d).

324 **ure 3b).** CAR⁺ and CAR⁻ nuclei were isolated by FACS, and
 325 the RNA was extracted for deep sequencing (CAR⁺: 8,500 nuclei/replicate, n=4;
 326 CAR⁻: 180,000 nuclei/replicate, n=4). On average, 1.97% of all nuclei were
 327 CAR⁺, a proportion similar to known percentage of cone photoreceptors in the mouse
 328 retina (Carter-Dawson and LaVail, 1979). To determine whether fixation was
 329 necessary for antibody penetration, we performed the FIN-Seq protocol with and
 330 without fixation. We found that the distinct CAR⁺ population was present only
 331 with fixation, suggesting that, unlike the NeuN antibody, fixation is necessary for
 332 optimal immunolabeling of CAR (Figure 3-figure supplement
 333
 334

1). cDNA sequencing libraries were generated using SMART-Seq v.4 and sequenced to a mean depth of 43 million (range: 37
 53 million reads/replicate) 75bp paired-end reads. The sequencing reads were analyzed, and the quality control parameters indicated successful sample separation and differential expression analysis (Figure 3-figure supplement 2). We found 5,260 DE genes (adjusted p -value < 0.05) between CAR⁺ and CAR⁻ nuclear populations.

To determine the cellular identity of the CAR⁺ population, we examined the top 50 differential expressed genes between CAR⁺ and CAR⁻ populations. Of the 16 genes enriched in the




Figure 3:

Isolation and sequencing of cone photoreceptor nuclei from the frozen human retina. (A) Schematic of FIN-Seq for the frozen human retina. Nuclei were extracted from the frozen retina and subsequently fixed in 4% PFA. Nuclei were then immunolabeled with an anti-CAR antibody and sorted. CAR⁺ and CAR⁻ populations were obtained and the nuclear RNA was sequenced. (B) Representative immunohistochemistry of an adult human retina section using the anti-CAR antibody (middle panel) and DAPI (left panel). CAR⁺ cone photoreceptors were localized to the uppermost layer of the ONL. (C) Heatmap of unbiased top 50 differentially expressed genes between CAR⁺ and CAR⁻ populations. Known cone photoreceptor markers (in red) were enriched in the CAR⁺ population. (D) Validation of new human cone photoreceptor markers by single molecule FISH. Expression levels for *DHRS3* and *RAB41* from the RNA-seq are indicated in the graphs (left panels). Both *DHRS3* and *RAB41* were expressed in the *ARR3*⁺ cone photoreceptors (arrows). ONL, Outer Nuclear Layer; INL, Inner Nuclear Layer; GCL, Ganglion Cell Layer. Scale bars; 50 μ m (b), 10 μ m (d).

CAR⁺ population, eight are known markers of human cone photoreceptors, identified by previous single cell RNA sequencing experiments (Figure 3c, cone markers in red) (Lukowski et al., 2018). We also performed single molecule FISH for two previously uncharacterized cone markers, *RAB41* and *DHRS3*, and found that they were specifically expressed in *ARR3*⁺ cone photoreceptors (Figure 3d). To determine whether other cell

type specific transcripts were enriched, we assessed the abundance of human markers for cones (*ARR3*, *GUCA1C*, *OPN1MW*, *PDE6C*, *PDE6H*), rods (*GNGT1*, *CNGA1*), bipolar cells (*VSX2*, *TRPM1*, *GRM6*), amacrine cells (*GAD1*), astrocytes / Müller glia (*GFAP*), Müller glia (*APOE*, *RLBP1*), and retinal ganglion cells (*SNCG*, *NEFL*) (Figure 3-figure supplement 3). We found an enrichment of human cone markers in the CAR⁺ pop-

360 ulation while all other cell type markers were enriched in the
361 CAR⁺ population. These results indicate that FIN-Seq success-
362 fully isolated and transcriptionally profiled cone photoreceptors
363 from frozen postmortem human retinas.

364 DISCUSSION

365 Technologies to enable transcriptional analysis of the human
366 CNS are rapidly expanding. At the tissue-level, distinct regions
367 of the fetal and adult human brain have been sampled for gene
368 expression analysis (Bossers et al., 2009; Dangond et al., 2004;
369 Dumitriu et al., 2012; Hauser et al., 2005; Hawrylycz et al.,
370 2012; Kang et al., 2011; Lederer et al., 2007; Miller et al., 2006;
371 Moran et al., 2006; Offen et al., 2009; Papapetropoulos et al.,
372 2006; Wang et al., 2006). Despite progress, these tissue-level
373 approaches cannot account for cellular heterogeneity of the hu-
374 man brain, an organ with tremendous cellular diversity. This is
375 important especially as it refers to human CNS disorders, where
376 histological studies have underscored the cell type specific na-
377 ture of cellular dysfunction and degeneration (Hartong et al.,
378 2006; Mitchell and Borasio, 2007; Sulzer and Surmeier, 2013).
379 To understand the transcriptional changes that accompany cel-
380 lular dysfunction in different types of CNS disorders, it is crit-
381 ical to isolate and analyze the specific neuronal populations af-
382 fected. These may be rare cell types within the tissue, further
383 underscoring the need for technologies that allow enrichment of
384 pre-defined cell types.

385 Recent developments of single cell RNA-seq technology
386 have enabled unbiased sampling of all cell types from a human
387 CNS tissue sample (Cherry et al., 2018; Darmanis et al., 2015;
388 Hodge et al., 2018; Lake et al., 2016; Lake et al., 2018; Liang
389 et al., 2019; Lukowski et al., 2018; Peng et al., 2019; Phillips
390 et al., 2018). However, for some types of studies, it is imprac-
391 tical to assess the gene expression changes in all cell types. If
392 the cell type of interest is known, bulk RNA-seq of isolated neu-
393 ronal populations is a complementary approach to quantify gene
394 expression more comprehensively in specific cells of interest.
395 Here, we developed a new method, FIN-Seq, to quantify gene
396 expression in isolated neuronal populations from frozen post-
397 mortem human CNS tissue. Bulk RNA sequencing can detect
398 low abundant transcripts and rare splice variants, which are of-
399 ten not detected in single cell or single nucleus RNA sequencing
400 (Arzalluz-Luque and Conesa, 2018; Liu and Trapnell, 2016).
401 We also showed that bulk nuclear sequencing could represent
402 more of the whole-cell transcripts compared to single nucleus
403 sequencing. FIN-Seq is a complementary approach to single
404 nucleus sequencing that can isolate and transcriptionally profile
405 user-defined cell types from frozen human CNS tissues. As sug-
406 gested by the data from cone photoreceptors, which comprise
407 only 2% of retinal cells, it may prove to be especially valuable
408 for deep profiling of rare cell types.

409 The challenge of applying FIN-Seq for some cell types is
410 the availability of suitable nuclear antibodies. With the rapid
411 progress of single cell sequencing, markers of molecularly dis-
412 tinct human neuronal subtypes are becoming available. For
413 most of these markers, however, no antibody exists. FIN-Seq
414 could greatly benefit from efforts to generate a validated anti-
415 body catalog such as the Protein Capture Reagents Program, in
416 which over 700 validated monoclonal antibodies against human

transcription factors have been produced (Venkataraman et al., 417
2018). For molecular markers without an antibody, FIN-Seq 418
could be further developed to isolate specific cell populations 419
using nuclear RNA by FISH techniques such as RNAscope or 420
SABER (Kishi et al., 2018; Klemm et al., 2014). Labeling 421
specific nuclear transcripts of human neuronal nuclei for down- 422
stream FACS and transcriptome sequencing will enable FIN-Seq 423
to capture any cell type of interest. 424

425 Taken together, FIN-Seq could enable transcriptional pro- 426
filing of specific, user-defined neuronal subtypes in the post- 427
mortem human CNS without a need for genetic labeling. Count- 428
ing only those from the NIH brain bank, over 16,000 post- 429
mortem samples are available, including those with neurological 430
disorders, and many of them are stored long-term as flash-frozen 431
samples. With FIN-Seq, we can start to interrogate the transcrip- 432
tional changes that accompany specific neuronal subtypes in the 433
adult human brain and identify molecular mechanisms underly- 434
ing cell type specific pathology.

435 MATERIALS AND METHODS

436 Mouse Brain Samples

437 All animals were handled according to protocols approved by the Institutional
438 Animal Care and Use Committee (IACUC) of Harvard University. For each bi-
439 ological replicate, the neocortex of P30 or adult (1+ years old) CD1 mice were
440 microdissected, flash-frozen in an isopentane/dry ice slurry, and stored at -80°C.

441 Frozen Human CNS Samples

442 Frozen Brodmann Area 4 (Primary Motor Cortex) samples of Patient 1569,
443 3529, 3589, 4340, and 5650 were obtained from Human Brain and Spinal Fluid
444 Resource Center at University of California, Los Angeles through the NIH Neu-
445 roBioBank. Patient 1569 is a 61-year-old male with no clinical brain diagnosis
446 and the postmortem interval was 9 hours. Patient 3529 is a 58-year-old male
447 with no clinical brain diagnosis and the postmortem interval was 9 hours. Patient
448 3589 is a 53-year-old male with no clinical brain diagnosis and the postmortem
449 interval was 15 hours. Patient 4340 is a 47-year-old male with no clinical brain
450 diagnosis and the postmortem interval was 12.5 hours. Patient 5650 is a 55-year-
451 old male with no clinical brain diagnosis and the postmortem interval was 22.6
452 hours. This IRB protocol (IRB16-2037) was determined to be not human sub-
453 jects research by the Harvard University-Area Committee on the Use of Human
454 Subjects.

455 Frozen eyes were obtained from Restore Life USA (Elizabethton, TN)
456 through TissueForResearch. Patient DRLU032618A is a 52-year-old female
457 with no clinical eye diagnosis and the postmortem interval was 8 hours. Pa-
458 tient DRLU041518A is a 57-year-old male with no clinical eye diagnosis and
459 the postmortem interval was 5 hours. Patient DRLU041818C is a 53-year-old
460 female with no clinical eye diagnosis and the postmortem interval was 9 hours.
461 Patient DRLU051918A is a 43-year-old female with no clinical eye diagnosis
462 and the postmortem interval was 5 hours. This IRB protocol (IRB17-1781) was
463 determined to be not human subjects research by the Harvard University-Area
464 Committee on the Use of Human Subjects.

465 Nuclei Isolation, Immunolabeling, and FACS

466 Nuclei were prepared as described previously (Krishnaswami et al., 2016), with
467 modifications. Thawed tissue was minced and incubated in 1% PFA (with 1 μ L
468 mL⁻¹ RNasin Plus (Promega, Madison, WI)) for 5 minutes. Nuclei were pre-
469 pared by Dounce homogenizing in 0.1% Triton X-100 homogenization buffer
470 (250 mM sucrose, 25 mM KCl, 5 mM MgCl₂, 10mM Tris buffer, pH 8.0, 1
471 μ M DTT, 1x Protease Inhibitor (Promega), Hoechst 33342 10 ng mL⁻¹ (Thermo
472 Fisher Scientific, Waltham, MA), 0.1% Triton X-100, 1 μ L mL⁻¹ RNasin Plus).
473 Sample was then overlaid on top of 20% sucrose bed (25 mM KCl, 5 mM
474 MgCl₂, 10mM Tris buffer, pH 8.0) and spun at 500xg for 12 minutes at 4°C.
475 The pellet was resuspended in 4% PFA (with 1 μ L mL⁻¹ RNasin Plus) and in-
476 cubated for 15 minutes on ice. The sample was spun at 2000xg for 5 minutes
477 at 4°C and the supernatant was discarded. The sample was then resuspended
478 in blocking buffer (0.5% BSA in nuclease-free PBS, 0.5 μ L mL⁻¹ RNasin Plus)
479 and incubated for 15 minutes. Sample was spun and the pellet was resuspended
480 and incubated in primary antibody (1:50 SATB2 antibody (Abcam, Cambridge,
481 UK), 1:100 BCL11B antibody (Abcam), 1:1000 CAR antibody (kind gift from

482 Dr. Sheryl Craft) in blocking buffer) for 30 minutes at 4°C. After washing 1x
483 with blocking buffer, the sample was incubated in secondary antibody (1:750
484 appropriate AlexaFluor secondary antibodies (Thermo Fisher Scientific)) for 30
485 minutes at 4°C. After 1x wash, the sample was passed through a 35µm filter
486 (Corning, Corning, NY) before proceeding to FACS. 2N nuclei were determined
487 by Hoechst histogram, and isolated populations were sorted into blocking buffer.
488 Sorted nuclei were spun at 3000xg for 7 minutes, and the supernatant was dis-
489 carded.

490 RNA isolation and library preparation

491 RNA was extracted using the RecoverAll Total Nuclear Isolation Kit (Thermo
492 Fisher Scientific). Crosslinking was reversed by incubating the nuclear pellet in
493 Digestion Buffer and Protease mixture (100 µL buffer and 4 µL protease) for 3
494 hours at 50°C. RNA-seq library was generated using the SMART-seq v.4 Ultra
495 Low Input RNA Kit (Takara Bio, Kusatsu, Japan) and Nextera XT DNA Library
496 Prep Kit (Illumina, San Diego, CA) according to protocol. Number of cycles
497 was determined based on the number of nuclei sorted. The cDNA library frag-
498 ment size was determined by BioAnalyzer 2100 HS DNA Assay (Agilent, Santa
499 Clara, CA). The libraries were sequenced as paired-end reads on HiSeq 2500 or
500 NextSeq 500.

501 RNA-seq data processing

502 Quality control of RNA-seq reads were performed using fastqc version
503 0.11.5 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). RNA-
504 seq reads were clipped and mapped onto the mouse genome (Ensembl
505 GRCm38.88) or human genome (Ensembl GRCh38.87) using STAR version
506 2.5 (Aken et al., 2017; Dobin et al., 2013). Parameters used were as fol-
507 lows: `-runThreadN 6 -readFilesCommand zcat -outSAMtype BAM Sorted-`
508 `ByCoordinate -outSAMunmapped Within -outSAMattributes Standard -`
509 `clip3pAdapterSeq -quantMode TranscriptomeSAM GeneCounts`

510 Alignment quality control was performed using Qualimap version 2.2.1
511 (Okonechnikov et al., 2016). Read counts were generated by HT-seq version
512 0.6.1 (Anders et al., 2015). Sample parameters used were as follows: `-i`
513 `gene_name -s no`

514 The resulting matrix of read counts were analyzed for differential expres-
515 sion by DESeq2 version 3.5 (Love et al., 2014). Samples with non-neuronal
516 cell contamination were discarded for analysis (BCL11B⁺ 3529 and BCL11B⁺
517 3589). For the DE analysis of human retina samples, any genes with more than
518 5 samples with zero reads were discarded. The R scripts used for differential
519 expression analysis is available in Supplementary Files.

520 Gene Set Enrichment Analysis

521 GSEA analysis was performed on the All vs. SATB2⁺ dataset using GSEA v3.0
522 (Subramanian et al., 2005). Gene set databases including markers that define
523 neuronal subtypes identified by Darmanis et al. (2015) and Lake et al. (2016)
524 were generated. Parameters used were as follows: Number of permutations:
525 1000; Enrichment statistic: weighted; Metric for ranking genes: Signal2Noise;
526 Min size: 0. To determine significance, we used the default FDR < 0.25 for all
527 gene sets.

528 RNAscope

529 P30 and adult mouse brains were perfused with 4% PFA and sectioned on a
530 cryostat at a thickness of 16 µm. Double *in situ* fluorescence hybridization was
531 performed using the RNAscope Fluorescent Multiplex assay according to pro-
532 tocol (Advanced Cell Diagnostics, Newark, CA). The following probes were
533 used for the mouse study: Satb2-C1 (Catalog : 413261), Satb2-C2 (Catalog:
534 420981-C2), Bcl11b-C3 (Catalog: 413271-C3), Ddit4l-C1 (Catalog: 468551),
535 Kcnn2-C1 (Catalog: 427971), Unc5d-C2 (Catalog: 480461-C2), and Rprm-C2
536 (Catalog: 466071-C2).

537 FFPE adult human cerebral cortex tissue from a 54-year-old female was
538 obtained from Abcam (ab4296). Chromogenic double *in situ* hybridization was
539 performed for the human brain tissue using the RNAscope 2.5 HD Duplex Assay
540 (Advanced Cell Diagnostics) according to protocol. Fluorescent Multiplex as-
541 say was used for the human retina tissue according to protocol (Advanced Cell
542 Diagnostics). The following probes were used for the human study: SATB2-
543 C2 (Catalog: 420981-C2), RORB-C1 (Catalog: 446061), UNC5D-C1 (Cata-
544 log: 459991), CRYM-C2 (Catalog: 460031-C2), GAD1-C1 (Catalog: 404031),
545 COL6A1-C1 (Catalog: 482461), ANXA1-C1 (Catalog: 465411), ARR3-C2
546 (Catalog: 486461-C2), DHRS3-C1 (Catalog: 504941), RAB41-C1 (Catalog:
547 559561).

548 Immunohistochemistry

549 P30 and adult mouse brains were perfused with 4% PFA and sectioned on a
550 vibratome at a thickness of 40 µm. Immunohistochemistry was performed as
551 previously described (Arlotta et al., 2005) with anti-SATB2 and anti-BCL11B
552 antibodies. FFPE adult human cerebral cortex tissue from a 54-year-old female

was obtained from Abcam (ab4296). The brain tissue was deparaffinized by 2x
xylene incubation (3 minutes each) followed by 1x 100% ethanol (3 minutes),
1x 95% ethanol (3 minutes), 1x 70% ethanol (3 minutes) washes. Antigen re-
trieval was performed in a citrate buffer (10mM Citric Acid, pH 6.0) in a rice
cooker with boiling water for 20 minutes. Subsequently, immunohistochemistry
was performed as described above with an additional step of incubation in True-
Black (Biotium, Fremont, CA) after incubation in blocking buffer to quench the
lipofuscin autofluorescence. For human eye immunohistochemistry, formalin-
fixed human postmortem eyes were obtained from Restore Life USA. Patient
DRLU101818C is a 54-year-old male with no clinical eye diagnosis and the
postmortem interval was 4 hours. Patient DRLU110118A is a 59-year-old fe-
male with no clinical eye diagnosis and the postmortem interval was 4 hours.
The retina was cryosectioned at 16 µm thickness. Immunohistochemistry was
performed as previously described (Arlotta et al., 2005) with anti-CAR antibody
(1:10,000).

568 Imaging

569 Fluorescent confocal images of the brain were acquired with Zeiss LSM 700
570 confocal microscope and analyzed with the ZEN Black software. Fluorescent
571 confocal images of the retina were acquired with Nikon Ti inverted spinning disk
572 microscope and analyzed with the NIS-Elements software. Brightfield color im-
573 ages of the human brain were acquired with AxioZoom V16 Zoom Microscope.

574 REFERENCES

- Aken, B.L., Achuthan, P., Akanni, W., Amode, M.R., Bersndorff, F., Bhai, J.,
Billis, K., Carvalho-Silva, D., Cummins, C., Clapham, P., et al. (2017). Ensembl
2017. Nucleic acids research 45.
Ameur, A., Zaghlool, A., Halvardson, J., Wetterbom, A., Gyllensten, U., Cave-
lier, L., and Feuk, L. (2011). Total RNA sequencing reveals nascent transcription
and widespread co-transcriptional splicing in the human brain. Nature structural
molecular biology 18, 1435-1440.
Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to
work with high-throughput sequencing data. Bioinformatics (Oxford, England)
31, 166-169.
Arlotta, P., Molyneaux, B.J., Chen, J., Inoue, J., Kominami, R., and Macklis,
J.D. (2005). Neuronal subtype-specific genes that control corticospinal motor
neuron development *in vivo*. Neuron 45, 207-221.
Arzalluz-Luque, A., and Conesa, A. (2018). Single-cell RNAseq for the study
of isoforms-how is that possible? Genome biology 19, 110.
Barthelson, R.A., Lambert, G.M., Vanier, C., Lynch, R.M., and Galbraith, D.W.
(2007). Comparison of the contributions of the nuclear and cytoplasmic com-
partments to global gene expression in human cells. BMC genomics 8, 340.
Bossers, K., Meerhoff, G., Balesar, R., van Dongen, J.W., Kruse, C.G., Swaab,
D.F., and Verhaagen, J. (2009). Analysis of gene expression in Parkinson's
disease: possible involvement of neurotrophic support and axon guidance in
dopaminergic cell death. Brain pathology (Zurich, Switzerland) 19, 91-107.
Carter-Dawson, L.D., and LaVail, M.M. (1979). Rods and cones in the mouse
retina. I. Structural analysis using light and electron microscopy. The Journal of
comparative neurology 188, 245-262.
Cherry, T.J., Yang, M.G., Harmin, D.A., Tao, P., Timms, A.E., Bauwens, M., Al-
likmets, R., Jones, E.M., Chen, R., DeBaere, E., et al. (2018). Epigenomic Pro-
filing and Single-Nucleus-RNA-Seq Reveal Cis-Regulatory Elements in Human
Retina, Macula and RPE and Non-Coding Genetic Variation. bioRxiv, 412361.
Dangond, F., Hwang, D., Camelo, S., Pasinelli, P., Frosch, M.P., Stephanopou-
los, G., Stephanopoulos, G., Brown, R.H., and Gullans, S.R. (2004). Molecu-
lar signature of late-stage human ALS revealed by expression profiling of post-
mortem spinal cord gray matter. Physiological genomics 16, 229-239.
Darmanis, S., Sloan, S.A., Zhang, Y., Enge, M., Caneda, C., Shuer, L.M., Hay-
den Gephart, M.G., Barres, B.A., and Quake, S.R. (2015). A survey of human
brain transcriptome diversity at the single cell level. Proceedings of the National
Academy of Sciences of the United States of America 112, 7285-7290.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics (Oxford, England) 29, 15-21.
Dumitriu, A., Latourelle, J.C., Hadzi, T.C., Pankratz, N., Garza, D., Miller, J.P.,
Vance, J.M., Foroud, T., Beach, T.G., and Myers, R.H. (2012). Gene expression
profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes un-
der its transcriptional regulation. PLoS genetics 8.
Grindberg, R.V., Yee-Greenbaum, J.L., McConnell, M.J., Novotny, M.,
O'Shaughnessy, A.L., Lambert, G.M., Araza-Bravo, M.J., Lee, J., Fishman,
M., Robbins, G.E., et al. (2013). RNA-sequencing from single nuclei. Proceed-
ings of the National Academy of Sciences of the United States of America 110,
19802-19807.

- 624 Habib, N., Avraham-Davidi, I., Basu, A., Burks, T., Shekhar, K., Hofree, M.,
625 Choudhury, S.R., Aguet, F., Gelfand, E., Ardlie, K., et al. (2017). Massively
626 parallel single-nucleus RNA-seq with DroNc-seq. *Nature methods*, 955-958.
627 Harb, K., Magrinelli, E., Nicolas, C.S.S., Lukianets, N., Frangeul, L., Pietri, M.,
628 Sun, T., Sandoz, G., Grammont, F., Jabaudon, D., et al. (2016). Area-specific
629 development of distinct projection neuron subclasses is regulated by postnatal
630 epigenetic modifications. *eLife* 5.
631 Hartong, D.T., Berson, E.L., and Dryja, T.P. (2006). Retinitis pigmentosa.
632 *Lancet* (London, England) 368, 1795-1809.
633 Hauser, M.A., Li, Y.-J.J., Xu, H., Noureddine, M.A., Shao, Y.S., Gullans, S.R.,
634 Scherzer, C.R., Jensen, R.V., McLaurin, A.C., Gibson, J.R., et al. (2005). Ex-
635 pression profiling of substantia nigra in Parkinson disease, progressive supranu-
636 clear palsy, and frontotemporal dementia with parkinsonism. *Archives of neuro-*
637 *logy* 62, 917-921.
638 Hawrylycz, M.J., Lein, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L.,
639 Miller, J.A., van de Lagemaat, L.N., Smith, K.A., Ebbert, A., Riley, Z.L., et
640 al. (2012). An anatomically comprehensive atlas of the adult human brain tran-
641 scriptome. *Nature* 489, 391-399.
642 Heiman, M., Schaefer, A., Gong, S., Peterson, J.D., Day, M., Ramsey, K.E.,
643 Surez-Farias, M., Schwarz, C., Stephan, D.A., Surmeier, D.J., et al. (2008). A
644 translational profiling approach for the molecular characterization of CNS cell
645 types. *Cell* 135, 738-748.
646 Hodge, R.D., Bakken, T.E., Miller, J.A., Smith, K.A., Barkan, E.R., Graybuck,
647 L.T., Close, J.L., Long, B., Penn, O., Yao, Z., et al. (2018). Conserved cell types
648 with divergent features between human and mouse cortex. *bioRxiv*.
649 Hrvatin, S., Deng, F., O'Donnell, C.W., Gifford, D.K., and Melton, D.A. (2014).
650 MARIS: method for analyzing RNA following intracellular sorting. *PLoS one* 9.
651 Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., Sousa, A.M.M.M.,
652 Pletikos, M., Meyer, K.A., Sedmak, G., et al. (2011). Spatio-
653 temporal transcriptome of the human brain. *Nature* 478, 483-489.
654 Kishi, J.Y., Beliveau, B.J., Lapan, S.W., West, E.R., Zhu, A., Sasaki, H.M., Saka,
655 S.K., Wang, Y., Cepko, C.L., and Yin, P. (2018). SABER enables highly multi-
656 plexed and amplified detection of DNA and RNA in cells and tissues. *bioRxiv*.
657 Klemm, S., Semrau, S., Wiebrands, K., Mooijman, D., Faddah, D.A., Jaenisch,
658 R., and van Oudenaarden, A. (2014). Transcriptional profiling of cells sorted by
659 RNA abundance. *Nature methods* 11, 549-551.
660 Kozlenkov, A., Li, J., Apontes, P., Hurd, Y.L., Byne, W.M., Koonin, E.V., Weg-
661 ner, M., Mukamel, E.A., and Dracheva, S. (2018). A unique role for DNA (hy-
662 droxy)methylation in epigenetic regulation of human inhibitory neurons. *Science*
663 *advances* 4.
664 Krishnaswami, S.R., Grindberg, R.V., Novotny, M., Venepally, P., Lacar, B.,
665 Bhutani, K., Linker, S.B., Pham, S., Erwin, J.A., Miller, J.A., et al. (2016).
666 Using single nuclei for RNA-seq to capture the transcriptome of postmortem
667 neurons. *Nature protocols* 11, 499-524.
668 Lacar, B., Linker, S.B., Jaeger, B.N., Krishnaswami, S.R., Barron, J.J., Kelder,
669 M.J.E.J.E., Parylak, S.L., Paquola, A.C.M.C.M., Venepally, P., Novotny, M., et
670 al. (2016). Nuclear RNA-seq of single neurons reveals molecular signatures of
671 activation. *Nature communications* 7, 11022.
672 Lake, B.B., Ai, R., Kaeser, G.E., Salathia, N.S., Yung, Y.C., Liu, R., Wildberg,
673 A., Gao, D., Fung, H.-L.L., Chen, S., et al. (2016). Neuronal subtypes and di-
674 versity revealed by single-nucleus RNA sequencing of the human brain. *Science*
675 (New York, NY) 352, 1586-1590.
676 Lake, B.B., Chen, S., Sos, B.C., Fan, J., Kaeser, G.E., Yung, Y.C., Duong, T.E.,
677 Gao, D., Chun, J., Kharchenko, P.V., et al. (2018). Integrative single-cell anal-
678 ysis of transcriptional and epigenetic states in the human adult brain. *Nature*
679 *biotechnology* 36, 70-80.
680 Lake, B.B., Codeluppi, S., Yung, Y.C., Gao, D., Chun, J., Kharchenko, P.V.,
681 Linnarsson, S., and Zhang, K. (2017). A comparative strategy for single-nucleus
682 and single-cell transcriptomes confirms accuracy in predicted cell-type expres-
683 sion from nuclear RNA. *Scientific reports* 7, 6031.
684 Lederer, C.W., Torrisi, A., Pantelidou, M., Santama, N., and Cavallaro, S.
685 (2007). Pathways and genes differentially expressed in the motor cortex of pa-
686 tients with sporadic amyotrophic lateral sclerosis. *BMC genomics* 8, 26.
687 Liang, Q., Dharmat, R., Owen, L., Shakoor, A., Li, Y., Kim, S., Vitale, A., Kim,
688 I., Morgan, D., Wu, N., et al. (2019). Single-nuclei RNA-seq on human retinal
689 tissue provides improved transcriptome profiling. *bioRxiv*, 468207.
690 Liu, S., and Trapnell, C. (2016). Single-cell transcriptome sequencing: recent
691 advances and remaining challenges. *F1000Research* 5.
692 Lobo, M.K., Karsten, S.L., Gray, M., Geschwind, D.H., and Yang, X.W. (2006).
693 FACS-array profiling of striatal projection neuron subtypes in juvenile and adult
694 mouse brains. *Nature neuroscience* 9, 443-452.
695 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
696 change and dispersion for RNA-seq data with DESeq2. *Genome biology* 15,
697 550.
698 Lukowski, S., Lo, C., Sharov, A., Nguyen, Q., Fang, L., Hung, S., Zhu, L.,
699 Zhang, T., Nguyen, T., Senabouth, A., et al. (2018). Generation of human neural
700 retina transcriptome atlas by single cell RNA sequencing. *bioRxiv*.
701 Macosko, E.Z., Basu, A., Satija, R., Nemes, J., Shekhar, K., Goldman, M.,
702 Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. (2015). Highly
703 Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter
704 Droplets. *Cell* 161, 1202-1214.
705 Miller, R.M., Kiser, G.L., Kaysser-Kranich, T.M., Lockner, R.J., Palaniappan,
706 C., and Federoff, H.J. (2006). Robust dysregulation of gene expression in sub-
707 stantia nigra and striatum in Parkinson's disease. *Neurobiology of disease* 21,
708 305-313.
709 Mitchell, J.D., and Borasio, G.D. (2007). Amyotrophic lateral sclerosis. *Lancet*
710 (London, England) 369, 2031-2041. Molyneaux, B.J., Arlotta, P., Menezes,
711 J.R., and Macklis, J.D. (2007). Neuronal subtype specification in the cerebral
712 cortex. *Nature reviews Neuroscience* 8, 427-437.
713 Molyneaux, B.J., Goff, L.A., Brettler, A.C., Chen, H.-H.H., Brown, J.R.,
714 Hrvatin, S., Rinn, J.L., and Arlotta, P. (2015). DeCoN: genome-wide analy-
715 sis of in vivo transcriptional dynamics during pyramidal neuron fate selection in
716 neocortex. *Neuron* 85, 275-288.
717 Moran, L.B., Duke, D.C., Deprez, M., Dexter, D.T., Pearce, R.K., and Graeber,
718 M.B. (2006). Whole genome expression profiling of the medial and lateral sub-
719 stantia nigra in Parkinson's disease. *Neurogenetics* 7, 1-11.
720 Nikouei, K., Muoz-Manchado, A.B., and Hjerling-Leffler, J. (2016). BCL11B/CTIP2
721 is highly expressed in GABAergic interneurons of the mouse
722 somatosensory cortex. *Journal of chemical neuroanatomy* 71, 1-5.
723 Offen, D., Barhum, Y., Melamed, E., Embacher, N., Schindler, C., and Rans-
724 mayr, G. (2009). Spinal cord mRNA profile in patients with ALS: comparison
725 with transgenic mice expressing the human SOD-1 mutant. *Journal of molecular*
726 *neuroscience* : MN 38, 85-93.
727 Okonechnikov, K., Conesa, A., and Garca-Alcalde, F. (2016). Qualimap 2:
728 advanced multi-sample quality control for high-throughput sequencing data.
729 *Bioinformatics* (Oxford, England) 32, 292-294.
730 Pan, Y., Ouyang, Z., Wong, W.H., and Baker, J.C. (2011). A new FACS ap-
731 proach isolates hESC derived endoderm using transcription factors. *PLoS one* 6.
732 Papapetropoulos, S., Ffrench-Mullen, J., McCorquodale, D., Qin, Y., Pablo,
733 J., and Mash, D.C. (2006). Multiregional gene expression profiling identifies
734 MRP56 as a possible candidate gene for Parkinson's disease. *Gene expression*
735 13, 205-215.
736 Pechhold, S., Stouffer, M., Walker, G., Martel, R., Seligmann, B., Hang, Y.,
737 Stein, R., Harlan, D.M., and Pechhold, K. (2009). Transcriptional analysis of
738 intracytoplasmically stained, FACS-purified cells by high-throughput, quantita-
739 tive nuclease protection. *Nature biotechnology* 27, 1038-1042.
740 Peng, Y.-R.R., Shekhar, K., Yan, W., Herrmann, D., Sappington, A., Bryman,
741 G.S., van Zyl, T., Do, M.T.H.T.H., Regev, A., and Sanes, J.R. (2019). Molecular
742 Classification and Comparative Taxonomics of Foveal and Peripheral Cells in
743 Primate Retina. *Cell* 176, 1222.
744 Phillips, M.J., Jiang, P., Howden, S., Barney, P., Min, J., York, N.W., Chu,
745 L.-F.F., Capowski, E.E., Cash, A., Jain, S., et al. (2018). A Novel Approach
746 to Single Cell RNA-Sequence Analysis Facilitates In Silico Gene Reporting of
747 Human Pluripotent Stem Cell-Derived Retinal Cell Types. *Stem cells* (Dayton,
748 Ohio) 36, 313-324.
749 Shekhar, K., Lapan, S.W., Whitney, I.E., Tran, N.M., Macosko, E.Z., Kowal-
750 czyk, M., Adiconis, X., Levin, J.Z., Nemes, J., Goldman, M., et al. (2016).
751 Comprehensive Classification of Retinal Bipolar Neurons by Single-Cell Tran-
752 scriptomics. *Cell* 166, 1308.
753 Siebert, S., Cabuy, E., Scherf, B.G., Kohler, H., Panda, S., Le, Y.-Z.Z., Fehling,
754 H.J., Gaidatzis, D., Stadler, M.B., and Roska, B. (2012). Transcriptional code
755 and disease map for adult retinal cell types. *Nature neuroscience* 15, 487.
756 Sigurgeirsson, B., Emanuelsson, O., and Lundeberg, J. (2014). Sequencing de-
757 graded RNA addressed by 3' tag counting. *PLoS one* 9.
758 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
759 Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al.
760 (2005). Gene set enrichment analysis: a knowledge-based approach for inter-
761 preting genome-wide expression profiles. *Proceedings of the National Academy*
762 *of Sciences of the United States of America* 102, 15545-15550.
763 Sulzer, D., and Surmeier, D.J. (2013). Neuronal vulnerability, pathogenesis, and
764 Parkinson's disease. *Movement disorders : official journal of the Movement*
765 *Disorder Society* 28, 715-724.
766 Tasic, B., Menon, V., Nguyen, T.N., Kim, T.K., Jarsky, T., Yao, Z., Levi, B.,
767 Gray, L.T., Sorensen, S.A., Dolbeare, T., et al. (2016). Adult mouse cortical
768 cell taxonomy revealed by single cell transcriptomics. *Nature neuroscience* 19,
769 335-346.
770 Telley, L., Govindan, S., Prados, J., Stevant, I., Nef, S., Dermitzakis, E., Dayer,
771 A., and Jabaudon, D. (2016). Sequential transcriptional waves direct the differ-

772 entiation of newborn neurons in the mouse neocortex. *Science* (New York, NY) 773 351, 1443-1446.
774 Venkataraman, A., Yang, K., Irizarry, J., Mackiewicz, M., Mita, P., Kuang,
775 Z., Xue, L., Ghosh, D., Liu, S., Ramos, P., et al. (2018). A toolbox of
776 immunoprecipitation-grade monoclonal antibodies to human transcription fac-
777 tors. *Nature methods* 15, 330-338.
778 Wang, X.-S.S., Simmons, Z., Liu, W., Boyer, P.J., and Connor, J.R. (2006). Dif-
779 ferential expression of genes in amyotrophic lateral sclerosis revealed by profil-
780 ing the post mortem cortex. *Amyotrophic lateral sclerosis* : official publication
781 of the World Federation of Neurology Research Group on Motor Neuron Dis-
782 eases 7, 201-210.
783 Yamada, H., Maruo, R., Watanabe, M., Hidaka, Y., Iwatani, Y., and Takano, T.
784 (2010). Messenger RNA quantification after fluorescence activated cell sorting
785 using intracellular antigens. *Biochemical and Biophysical Research Communi-
786 cations* 397, 425-428.
787 Zeisel, A., Muoz-Manchado, A.B., Codeluppi, S., Linnerberg, P., La Manno,
788 G., Jurus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., et al. (2015).
789 Brain structure. Cell types in the mouse cortex and hippocampus revealed by
790 single-cell RNA-seq. *Science* (New York, NY) 347, 1138-1142.

Acknowledgments: We would like to thank former and current members of the 791
Arlotta and Cepko Labs for the insightful discussion and feedback. We thank D. 792
Richardson, Harvard Center for Biological Imaging, P.M. Llopis, R. Stephansky, 793
and the MicRoN core at Harvard Medical School for their assistance with mi- 794
croscopy. We thank S.H. Sui, V. Barrera, and M. Ziller for their assistance with 795
bioinformatics. We thank S. Craft for sharing of the hCAR antibody. We thank 796
C. Araneo, F. Lopez, and the Flow Cytometry Core Facility for their assistance 797
with flow cytometry. 798

Author Contributions: R.A., E.Z., H.-H.C., and P.A. conceived the work and 799
designed the experiments. R.A. performed the majority of the experiments 800
and analyzed the data. E.Z. and P.A. conceived the method. E.Z. and H.-H.C. 801
assessed feasibility in preliminary steps. R.A., P.A., and C.L.C. wrote the 802
manuscript. E.Z. edited the manuscript. N.C.C. and H.-H.C. assisted with the 803
FACS. S.K. assisted with the initial antibody screening for the FACS. P.A. and 804
C.L.C. supervised the brain and retina aspects of the project, respectively. 805

Declaration of Interests: A provisional US patent has been filed based on this 806
work. 807